Cigarette Maker BAT Announces The Launch Of Vaccine Trial

British cigarette maker BAT said that its US biotech division Kentucky BioProcessing will launch trials of a potential coronavirus vaccine.

British cigarette maker BAT said Wednesday that its US biotech division Kentucky BioProcessing will launch trials of a potential coronavirus vaccine, developed using tobacco plant technology.

interesting reading:  Personalised Nutrition Explains Why Your Diet Plan Is Not Working

The group said the US food and Drug Administration has approved its application for a vaccine candidate, paving the way for an initial phase one clinical trial in 180 adults.

Study results are expected in mid-2021, when the group hopes to progress to a phase two trial on the project, which is being run on a not-for-profit basis.

interesting reading:  Minister Warns Against Sale And Use Of Polythene Bags

“The candidate vaccine has been developed using KBP’s innovative fast-growing plant-based technology,” it said in a statement, adding enrollment for the trial will begin shortly.

“This unique approach has a number of possible advantages, including the rapid production of the vaccine’s active ingredients in around six weeks, compared to several months using conventional methods.

interesting reading:  PTA Gets ISO 9001: 2015 Certification For Consumer Protection Division

“The candidate vaccine also has the potential to be stable at room temperature, which could be a significant advantage for healthcare systems and public health networks worldwide.” BAT, whose best-selling cigarettes include Dunhill and Lucky Strike, acquired Kentucky BioProcessing with its 2016 purchase of US group Reynolds.

Originally Published at Urdu Point

Leave a Reply

Your email address will not be published. Required fields are marked *

Captcha loading...